Der Browser den Sie verwenden ist sehr alt.

Wir können daher nicht sicherstellen, dass jede Funktion (Gestaltung, Bilder und zusätzliche Funktionen) dieser Internetseite im vollen Umfang zur Verfügung steht. Bitte nutzen Sie eine aktuellere Browserversion.
Wir bitten um Ihr Verständnis.
Startseite > Forschung und Lehre > AG Braun: Tumor heterogeneity and treatment response in pancreatic cancer

AG Braun: Tumor heterogeneity and treatment response in pancreatic cancer

Group members

Bild von Rüdiger Braun
Dr. med. Rüdiger Braun
Klinik für Chirurgie
Assistenzarzt
Telefon Lübeck: 0451 500-40126 | Fax: -40104

 

Bild von Ulrich Wellner
PD Dr. med. Ulrich Wellner
Klinik für Chirurgie
Oberarzt
Telefon Lübeck: 0451 500-40117 | Fax: -40104

 

cand. med. Benedikt Färber

cand. med. Lena Anthuber

Outline

Our group focuses on preclinical models of pancreatic cancer to test therapy response ex vivo and facilitate personalized patient treatment. Underlying molecular mechanisms of treatment resistance in pancreatic cancer are poorly understood. There has been emerging evidence over the last few years that intratumoral heterogeneity (ITH) is a key determinant in tumor biology, treatment response and ultimately patient survival. Our group aims to establish clone-specific transcriptomic and proteomic profiles associated with distinct treatment response using classical cell line models.

Most currently used preclinical models such as cell lines and xenografts lack the specific tumor microenvironment and therefore allow only limited response prediction. Thus, our group also focuses on organotypic slice cultures which comprise an intact multicellular tissue composition. These cultures can be used rapidly to test for their respective response to drugs in a multicellular, heterogenous environment ex vivo and subsequent downstream analyses such as profiling of the transcriptome and proteome.

Collaborators

Dr. Matthias Brandenburger, Fraunhofer EMB, Lübeck
PD Dr. Peter Bronsert, Institute for Pathology, University of Freiburg, Freiburg
Prof. Dr. Thomas Ried, National Cancer Institute, Bethesda, MD, USA
Prof. Dr. Oliver Schilling, Institute for Surgical Pathology, University of Freiburg, Freiburg

Funding

Clinician Scientist School Lübeck (DFG #413535489)
Junior Funding Program of the University of Lübeck
Werner und Klara Kreitz Stiftung

Selected publications

Braun R, Anthuber LM, Wangsa D, Lack J, McNeil NE, Heselmeyer-Haddad K, Torres I, Wangsa D, Brown M, Hirsch D, Tubbs A, Auslander N, Brauer PR, Cam M, Sackett DL, Habermann JK, Nussenzweig A, Ruppin E, Zhang Z, Rosenberg DW, Ried T. Single cell-derived primary rectal carcinoma cell lines reflect intratumor heterogeneity associated with treatment response. Clin Cancer Res. 2020; 26(13):3468-3480

Wangsa D*, Braun R*, Stuelten CH, Brown M, Bauer KM, Emons G, Weston LA, Hu Y, Yang HH, Vila-Casadesús M, Lee MP, Brauer P, Warner L, Upender M, Hummon AB, Camps J, Ried T. Induced Chromosomal Aneuploidy Results in Global and Consistent Deregulation of the Transcriptome of Cancer Cells. Neoplasia 2019, 21(7): 721-729, *authors contributed equally

Braun R*, Ronquist S*, Wangsa D, Chen H, Anthuber L, Gemoll T, Wangsa D, Koparde V, Hunn C, Habermann JK, Heselmeyer-Haddad K, Rajapakse I, Ried T. Single chromosome aneuploidy induces genome-wide perturbation of nuclear organization and gene expression. Neoplasia 2019, 21(4): 401-412, *authors contributed equally

Wangsa D, Braun R, Schiefer M, Gertz EM, Bronder D, Quintanilla I, Padilla-Nash HM, Torres I, Hunn C, Warner L, Buishand FO, Hu Y, Hirsch D, Gaiser T, Camps J, Schwartz R, Schäffer AA, Heselmeyer-Haddad K, Ried T. The Evolution of Single Cell-derived Colorectal Cancer Cell Lines is Dominated by the Continued Selection of Tumor Specific Genomic Imbalances, Despite Random Chromosomal Instability. Carcinogenesis 2018, 39(8): 993-1005

 

 


DKG Onkologisches Zentrum BoxDKG Darmkrebszentrum BoxDKG Pankreaskarzinom Zentrum BoxDKB Speiseroehrenkrebs Zentrum Box

 

DKB-Vizeralonkologisches-Zentrum-HL